Suboxone Tooth Decay: A Case-Acquisition Window for Plaintiff Firms

Suboxone case acquisition for law firms remains economically viable in 2026 because the claimant pool is substantially undersaturated compared to legacy mass torts, while the MDL discovery phase continues to validate liability through FDA's January 2022 black-box warning. Bellwether trials scheduled for 2025–2026 are establishing damages benchmarks. For firms evaluating capital deployment, the critical variables are cost-per-signed-case, geographic targeting efficiency, and retention rates before settlement pressure compresses case value across the docket.

This post breaks down the real business of building a Suboxone tooth-decay practice: where the cases are, what they cost to acquire, how to screen and retain them, and what the litigation timeline means for your firm's return. I'll draw on 15+ years of mass tort advertising experience and the actual channel performance we've tracked across 600+ plaintiff law firms managing $250M+ in ad spend.

The Litigation Landscape: Why Suboxone Case Acquisition for Law Firms Matters Now

MDL 3092, based in the Northern District of Ohio under Judge Dan Polster, consolidated over 3,000 plaintiffs as of late 2023 and the docket continues to grow. Indivior Inc., the manufacturer of brand-name Suboxone film, is the primary defendant, with Aquestive Therapeutics (developer of the sublingual film delivery system) as a secondary target. This structure is crucial for your case valuation and settlement negotiations: single primary defendant, clear failure-to-warn theory, and a regulatory anchor that will survive summary judgment.

The FDA's 2022 black-box warning is the spine of plaintiff liability. The agency warned that Suboxone sublingual film causes severe dental erosion, tooth decay, tooth fractures, and tooth loss—even in patients with no prior dental disease. That warning is an admission by the regulator that the product-injury link is real and foreseeable. For a jury, or for settlement negotiators, it's nearly impossible for the defense to argue "we didn't know." What they'll argue instead is comparative fault, case-specific causation weakness, or damages capping. But liability is not your uphill battle here.

No verdicts have been returned yet, and no meaningful settlement agreements have been announced. The litigation is firmly in discovery. That means two things: (1) case valuations are still fluid and informed by discovery, not precedent; (2) firms investing in Suboxone case acquisition for law firms right now are building inventory ahead of the bellwether phase, not following a settlement trend. This is an advantage if your firm has capital and patience. It's a risk if your firm needs immediate case monetization.

Bellwether trials are estimated for 2025–2026. If Indivior loses the early trials—and loses badly—settlement pressure will accelerate. If verdicts are modest or split, settlement takes longer and case values plateau lower. Either way, your acquisition spend in 2024–2025 will significantly shape your firm's position in the settlement queue and your per-case profitability. Firms that build volume now and hold will benefit from settlement momentum. Firms that wait will compete for residual claimants at higher cost per case.

The Claimant Pool: Volume, Saturation, and Geographic Concentration

Suboxone is prescribed nationwide for opioid use disorder (OUD) treatment. Buprenorphine/naloxone (the active combo in Suboxone) is a front-line medication for medication-assisted treatment (MAT). The prescribing footprint is enormous: all 50 states, but with heavy concentration in regions with high opioid epidemic impact—Appalachia, the Midwest, rural areas, and post-industrial urban centers.

How many people took Suboxone film for 6+ months and developed significant tooth decay or tooth loss? The real number is unknowable, but epidemiological signals are strong. Buprenorphine has been in use since 2002, but the sublingual film formulation (the problematic delivery mechanism) gained significant market share after 2010. By the time of the 2022 FDA warning, millions of patients had been exposed to the film. Conservative estimates suggest 200,000–500,000 people in the U.S. have taken Suboxone film long enough to develop notable dental injury. The MDL's current 3,000+ plaintiff count represents a tiny fraction of the addressable pool.

Why such low penetration relative to exposure? A few reasons: (1) Suboxone is dispensed in specialty treatment settings, not general medical practice; patients often lack reliable legal marketing contact points. (2) OUD patients face stigma and legal barriers (some fear seeking legal counsel if they have criminal histories). (3) The dental injuries, while severe, are often attributed to "drug use" or "bad teeth" by patients themselves, not to a specific medication failure. (4) Very little advertising has been deployed into the Suboxone dental space relative to other mass torts—the plaintiff bar has been cautious.

From a case-acquisition standpoint, this is an uncluttered market. You won't face the saturation and CPL inflation you'd encounter in, say, talc or hip-implant litigation. Geographic targeting works. Digital channels haven't been hammered. Organic search volume is modest but growing. The claimant pool is still there, largely untouched by competitor plaintiff firms. If your firm moves on Suboxone case acquisition for law firms in the next 12–18 months, you'll capture volume at lower cost per signed case than you would in 2026 or later.

Advertising Economics: Cost Per Lead and Cost Per Signed Case

For Suboxone tooth-decay case acquisition, here's what we've observed across MTAA's network:

Cost Per Lead (CPL): $8–18 per qualified lead, depending on channel and targeting specificity. Suboxone is a narrower tort than talc (fewer Google searches, less competitor bidding on keywords), so CPL is lower than you'd see in mass-market consumer torts. Facebook and Google search dominate the channel mix. YouTube and TikTok work for younger OUD patient populations, but conversion is less reliable. Direct mail to medical providers and treatment centers is emerging as a high-intent supplementary channel but requires better data append.

Cost Per Signed Case: $500–1,500 per executed retainer, depending on your intake efficiency and follow-up discipline. This assumes a 25–45% lead-to-intake rate (many leads don't respond to callbacks; some fail qualification). If you run a 30-CPL campaign pulling 1,000 leads per month, and 35% intake to signed case, you're looking at roughly 105 new cases per month at a blended cost of around $1,000–1,200 per case. That math works if your average case value is in the $15,000–50,000 range (pre-settlement, for a firm share) or if you're building volume for a future settlement wave.

Which channels work best:

  • Google Search: "Suboxone tooth decay lawsuit," "Suboxone dental injury," "Suboxone lawsuit," "tooth loss Suboxone." Keyword volume is 500–800 monthly searches (modest, but high intent). CPC averages $3–7. You'll be bidding against competing plaintiff firms, but competition is still light. Landing-page quality and intake form friction matter enormously—simplify the form to three fields and you'll see 15–25% improvement in conversion.
  • Facebook & Instagram: Carousel and video ads targeting 30–60-year-old users in high-opioid-use states. Audience overlap with addiction recovery interest lists works well. CPL here runs $8–14. Creative should emphasize dental injury severity, the FDA warning, and no-cost case reviews for attorneys, not claimants. Video testimonials from clients describing tooth loss are high-performing.
  • Direct mail & Treatment Center Partnerships: Identify methadone clinics, buprenorphine prescribers, and recovery centers. Develop referral relationships or drop mail to high-concentration areas (Appalachia, Rust Belt). CPL is higher ($15–25), but lead quality and intake rate jump to 40–60% because the audience is pre-qualified and present in a trusted environment.
  • SEO & Content: Long-tail blog content around "Suboxone dental injury" and "tooth decay from buprenorphine" ranks quickly because competition is minimal. Organic search volume builds slowly but is cumulative and low-cost. Pair this with a paid search budget and you compound efficiency gains.

Creative angles that convert: Focus on severity (tooth loss, full extractions, denture dependency), regulator failure (FDA warning), and the patient's loss of dignity or quality of life tied to dental reconstruction cost. Emphasize that you're looking for serious cases with clear causation (6+ months of film use, significant decay that developed during treatment, dental records confirming pre-Suboxone dental health). Avoid victim-focused language; frame the case as a business opportunity for your firm with a defined claimant pool.

Intake and Qualification: Screening Cases on the Firm Side

Not every lead is a signed case, and not every signed case is a keeper. Qualification is where Suboxone case acquisition for law firms separates efficient firms from cash-flow disasters.

Red flags to screen out early:

  • Pre-existing severe dental disease or poor oral hygiene reported by the prospect (comparative fault risk).
  • Suboxone use for less than 6 months before injury onset (causation is weaker; easier for defense to argue coincidence or other causes).
  • Injuries that developed after the claimant stopped taking Suboxone film (injury must be proximate to active use or immediately after).
  • No dental records or expert-corroborable evidence of baseline dental health before Suboxone use (damages become speculative without before/after documentation).
  • Claimants with active criminal charges or credibility issues (jury perception risk in bellwether trials; defense will attack witness reliability).

Green-light case characteristics:

  • Clear documented timeline: Suboxone film use for 12+ months; dental injury developed during treatment or within 6 months of discontinuation.
  • Baseline dental health confirmed (pre-Suboxone dental records, patient testimony, family corroboration).
  • Severe injury: tooth loss, multiple extractions, root canals, or significant reconstruction costs ($10,000–50,000 in documented dental work).
  • Patient credibility: stable housing, employment or clear OUD recovery story, no active criminal matters, able to participate in depositions and trials if needed.
  • Medical records showing buprenorphine prescribing and duration; ideally, prescriber notes about the sublingual film formulation (not tablets or patches, which have lower dental risk).

Intake flow matters. When a lead calls or fills out a web form, your intake paralegal should ask: (1) How long were you on Suboxone film? (2) Did you have any major dental problems before starting Suboxone? (3) When did the tooth problems start? (4) Have you had dental work done or extracted teeth? (5) Do you have dental records from before and after? Quick qualifying calls (3–5 minutes) will eliminate 30–40% of leads before they hit your case-management system. The remaining 60–70% move to detailed intake, retainer execution, and medical records gathering.

Retainer structure: Most plaintiff firms use a contingency model (1/3 of recovery after costs). For Suboxone cases, this is standard. Ensure your retainer clearly defines (1) the scope of representation (MDL and bellwether trials only, or ongoing coverage if case gets stayed post-settlement); (2) cost-shifting for medical records, lien notices, and expert reports; (3) settlement authority thresholds (does the client need to approve a settlement offer, or do you have discretion within a range?). Keep retainers simple and signed early. Cases that sit unsigned for 30+ days have dramatically lower retention rates.

How MTAA Approaches Suboxone Case Acquisition for Law Firms

At Mass Tort Ad Agency, we've managed Suboxone campaigns for 12+ plaintiff firms to date, deploying roughly $2.5–3.5M in paid media spend across search, social, and supplemental channels since 2022. Here's how we structure it:

Campaign setup: We start with a cost-plus model: you pay the actual ad spend (Facebook, Google, whatever channels we deploy) plus a 15% management fee. No hidden costs, no proprietary media buys. Transparency on spend and ROI from day one. For a firm targeting 150–200 signed Suboxone cases per year, we typically recommend a $50,000–$100,000 monthly ad budget, scaled geographically to high-opioid-use regions (Ohio, West Virginia, Kentucky, Pennsylvania, Michigan, etc.).

Channel allocation: We typically split budget 50% Google Search + SEO, 35% Facebook/Instagram, 15% testing (direct mail, YouTube, or treatment-center partnerships). Search captures immediate intent. Social builds awareness and reach in high-exposure regions. Testing channels identify emerging opportunities and often uncover hidden lead sources (e.g., recovery app partnerships, peer-support forums).

Landing page and intake: We design conversion-focused landing pages that load in under 2 seconds, explain the case in plain language, and embed a one-click lead form (not a full application). Calls-to-action are attorney-facing ("Our firm is investigating Suboxone dental injury cases" or "Refer your Suboxone clients here"), not claimant-facing. Lead forms ask for name, phone, zip code, and a one-line description of the injury. Longer forms tank conversion by 40–60%.

Intake support: We provide call scripts, intake paralegal training, and follow-up sequences (email and SMS reminders to non-responders). Most firms lose 30–40% of leads to poor follow-up. We've built templated sequences that recover 15–25% of those lost leads with minimal manual effort.

Case performance tracking: We report monthly on CPL, CPC, conversion rates, and cost per signed case. We also track retention (how many signed cases actually stick vs. how many are withdrawn or drop out). This data informs budget reallocation and channel optimization. If a geographic market underperforms, we scale down. If an audience segment converts at 2x the average, we expand.

Settlement timing: We coordinate campaign intensity with litigation milestones. As bellwether trials approach (2025–2026), we typically recommend maintaining or increasing ad spend to capture demand before settlement pressure breaks. Once settlement is announced and claimant-deadline marketing kicks in, we shift to a lower-touch, organic retention strategy.

The Competitive Landscape and Your Firm's Window

As of mid-2024, Suboxone case acquisition for law firms remains relatively uncompetitive. You won't see the noise and CPL inflation that defines talc, 3M earplugs, or Roundup litigation. The plaintiff bar is still building awareness. That's your advantage. But it's also fleeting. Once 2–3 large firms deploy serious capital into the space, CPL will climb 50–100%, and the remaining addressable claimant pool will fragment across more competitors.

The firms that have moved first (we work with several) are positioning inventory for the bellwether phase. If Indivior loses early trials decisively, those firms will have 500–2,000 cases ready to hand to settlement counsel. If verdicts are narrow or split, those firms still have volume to sustain their practice through a prolonged discovery fight. Either way, they win. Firms that wait to see how bellwethers turn out will enter the market with less leverage and higher acquisition costs.

Ready to Build Your Caseload?

Get a free campaign analysis from Mass Tort Ad Agency.

$250M+ in mass tort Facebook ad spend. 600+ law firms served. Transparent cost-plus pricing with no hidden fees.

Schedule a Free Consultation →

Frequently Asked Questions: Advertising Suboxone Tooth Decay Cases

What does it cost a law firm to acquire Suboxone Tooth Decay cases?

Acquisition cost depends on the channel, creative, and qualification bar, and is best measured as cost per signed retainer rather than cost per lead. Mass Tort Ad Agency runs these campaigns at ad spend plus a 15% management fee with no hidden markups, so firms see the true per-case economics.

How do plaintiff firms advertise Suboxone Tooth Decay cases efficiently?

Most signed volume comes from targeted Facebook and Instagram campaigns paired with a tight intake and qualification process. MTAA manages these end to end across 100+ active mass torts for 600+ firms.